Category: BehaVR

  • PharmaShots Weekly Snapshots (October 18 – 22, 2021)

    LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, Atopic Dermatitis Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China Published: 22 Oct, 2021 | Tags: […]

  • Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS Disorders

    Shots: BehaVR to receive $5M up front, ~$18M in development milestone and R&D support along with commercial & operational support fees and is eligible to receive $140M in milestone upon commercial success along with royalties on global sales of the digital therapeutic products The collaboration combines BehaVR’s development capabilities with SDP’s expertise to develop prescription […]

  • To help tackle healthcare worker burnout, start talking about it

    Healthcare staff are working through immense loss, grief and uncertainty to provide care during the Covid-19 pandemic. As organizations think about how to support their staff, speakers at a MedCity INVEST panel said they must first talk about it openly and provide a safe space for workers to discuss their feelings.